Hoffmann-la Roche Inc.

Sloan-kettering Institute for Cancer Research

Harold Leon Newmark

William Joseph Mergens

Alexander S Emodi

Leonard Joseph Scialpi

Martin Howard Infeld

Prabhakar R Sheth

Jacques L Tossounian

Armin Hermann Ramel

Weldon Courtney McGregor

This invention provides a method of inducing cell differentiation in a subject and methods of treating leukemia, thalassemia, or sickle cell anemia by administration to the subject of one or more oral bolus doses of a pharmaceutical composition comprising an effective amount of one or more butyryl glycerides and a pharmaceutically acceptable carrier. This invention also provides a method of treating a surface or skin disorder in a subject by topical administration to the subject of a pharmaceutical composition comprising an effective amount of one or more butyryl glycerides and a pharmaceutically acceptable carrier.

Butyric ester cyto-differtiating agents

The effect of a controlled release, hydrodynamically balanced dosage formulation containing both an aqueous phase N-nitroso compound blocking agent and a lipid phase N-nitroso compound blocking agent in preventing the formation of nitrosamines and nitrosamides in the stomach is disclosed.

Prevention of N-nitroso compound formation in vivo

Thymosin fraction 5 has been widely employed recently in the clinical investigation of this thymic hormone. This material is a hormonally active proteinaceous composition which is involved in the regulation of cell-mediated immunity. The present disclosure provides a solid, stable, endotoxin and pyrogen free thymosin fraction 5 composition suitable for reconstitution for injection.

Stabilized thymosin composition and method

Compounds represented by the formula ##STR1## wherein A is ##STR2## R is hydrogen, substituted or unsubstituted lower alkenyl or alkyl of 1 to 8 carbon atoms in the alkyl chain, phenyl or substituted phenyl, R.sub.1 is phenyl, substituted phenyl or lower alkyl substituted with phenyl, hydrates thereof, and Pharmaceutically acceptable basic salts of said compounds or hydrates, useful as antibacterial therapeutic agents in the treatment of infectious diseases caused by Gram-positive and Gram-negative bacteria, particularly Gram-negative bacteria and particularly advantageous because of their stability in aqueous solution are disclosed.

Semisynthetic penicillins

High potency compositions of vitamin A acetate and/or vitamin A alcohol stabilized against the formation of crystals by vitamin A palmitate are provided.

High potency vitamin A compositions

Stabilization of the copper II complex of 6-methoxy-1-phenazinol 5,10-dioxide, when used in a variety of dosage forms, is achieved by the addition of a 2-20% molar excess of copper ions to the specific dosage form.

Stabilization of copper complexes of 6-methoxy-1-phenazinol 5,10-dioxide

The preparation of relatively stable injectable solutions from dry powder formulations containing from 1.0 to 2.0 moles of anhydrous sodium carbonate per mole of amoxicillin free acid is disclosed. The solutions are suitable for administration by intravenous and intramuscular injection and intravenous drip.

Stable amoxicillin dosage form

The amount of nitrogen dioxide in tobacco smoke is materially reduced by bringing the smoke into contact with uncombusted tobacco having dispersed therein an effective amount of a composition comprising a pharmaceutically acceptable salt of ascorbic acid or erthorbic acid or mixtures of such salts with their respective acids wherein the molar ratio of acid to salt does not exceed about 3:1.

Growing community of inventors

Maplewood, NJ, United States of America

Harold Leon Newmark